BelgiumTuberculosis profile
Population  2017 11 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.061 (0.059–0.063) 0.54 (0.52–0.55)
Mortality (HIV+TB only) 0.013 (<0.01–0.019) 0.12 (0.08–0.17)
Incidence  (includes HIV+TB) 1.1 (0.96–1.3) 9.8 (8.4–11)
Incidence (HIV+TB only) 0.087 (0.072–0.1) 0.76 (0.63–0.91)
Incidence (MDR/RR-TB)** 0.029 (0.013–0.05) 0.25 (0.12–0.43)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.053 (0.051–0.054) 0.35 (0.32–0.38) 0.41 (0.37–0.44)
Males 0.057 (0.055–0.059) 0.65 (0.58–0.73) 0.71 (0.62–0.79)
Total 0.11 (0.1–0.11) 1 (0.86–1.2) 1.1 (0.96–1.3)
TB case notifications, 2017  
Total cases notified 972
Total new and relapse 916
          - % tested with rapid diagnostics at time of diagnosis 53%
          - % with known HIV status 56%
          - % pulmonary 71%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 82% (71–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.07 (0.06–0.08)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 43 8%
          - on antiretroviral therapy    
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  16
(6–25)
Estimated % of TB cases with MDR/RR-TB 1.6% (0.66–3.3) 8.8% (1.9–24)  
% notified tested for rifampicin resistance 58% 77% 729
MDR/RR-TB cases tested for resistance to second-line drugs   5
Laboratory-confirmed cases MDR/RR-TB: 8, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 7, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 82% 973
Previously treated cases, excluding relapse, registered in 2016 86% 57
HIV-positive TB cases registered in 2016 63% 32
MDR/RR-TB cases started on second-line treatment in 2015 100% 14
XDR-TB cases started on second-line treatment in 2015 100% 2
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-12-11 Data: www.who.int/tb/data